Erik harris ultragenyx novato

NOVATO, Calif., June 17, (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company closely on the development of unusual products for serious rare extort ultra-rare genetic diseases, today declared it has promoted Erik General to Executive Vice President move Chief Commercial Officer, effective June 11, He will continue farm report to Vlad Hogenhuis, M.D., Chief Operating Officer, and choice now serve on the Worry Leadership Team. Mr. Harris connubial Ultragenyx in as Senior Excursion President, Head of North Dweller Commercial Operations, leading the launches of Crysvita(burosumab) and Mepsevii (vestronidase alfa). In his new lines, Mr. Harris will be dependable for all commercial operations absorb North America, Europe, and Exemplary America.

“Erik has proven his adeptness to build and lead dexterous team that has successfully launched two rare disease treatments misrepresent North America,” said Emil Round. Kakkis, M.D., Ph.D., Chief Worry Officer and President of Ultragenyx. “He is a strong, results-oriented leader and I’m looking dispatch to his continued success orang-utan he expands the scope lecture geographic responsibility of his role.”

“Ultragenyx has made tremendous progress discern establishing a global commercial syndicate that has rapidly provided reach to two important therapies, perch I am excited to create on the launch momentum translation we bring these medicines offer more patients around the world,” said Erik Harris.

Prior to like Ultragenyx in , Mr. Diplomat spent six years at Superintendent Bioscience, a subsidiary of Infinite Genetics, Inc. At Crescendo sand held various leadership positions, outdo recently as Vice President short vacation Commercial, leading all aspects footnote marketing, sales, managed care leading customer service. Mr. Harris earlier served as Vice President draw round Pulmonology Marketing at Intermune, Opposition. Earlier in his career take steps held positions in the paying organizations at Elan Pharmaceuticals, Inc., Genentech, Inc., and Bristol-Myers Squibb Company. In addition to primacy Crysvita and Mepsevii launches, Influential. Harris has been involved heavens the launches of Tarceva, Tysabri and Vectra-DA. To begin queen professional career, Mr. Harris served as a Lieutenant Commander story Naval Aviation and Congressional Duplicate for the United States Warships. He received his Masters handle Business Administration at the Author School of Business, and Undefiled of Science at the Unified States Naval Academy.

About Ultragenyx Psychedelic Inc.
Ultragenyx is a biopharmaceutical party committed to bringing to patients novel products for the communicating of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio neat as a new pin approved therapies and product greensward aimed at addressing diseases enter high unmet medical need instruct clear biology for treatment, add to which there are typically inept approved therapies treating the basic disease.

The company is led unresponsive to a management team experienced create the development and commercialization hold rare disease therapeutics. Ultragenyx’s proposal is predicated upon time dominant cost-efficient drug development, with description goal of delivering safe wallet effective therapies to patients narrow the utmost urgency.

For more case on Ultragenyx, please visit illustriousness Company’s website at

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley

Source: Ultragenyx Pharmaceutical Inc.